Details for Patent: 8,981,103
✉ Email this page to a colleague
Which drugs does patent 8,981,103 protect, and when does it expire?
Patent 8,981,103 protects GENVOYA, STRIBILD, and VITEKTA, and is included in three NDAs.
Protection for GENVOYA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-four patent family members in twenty-eight countries.
Summary for Patent: 8,981,103
Title: | Stable crystal of 4-oxoquinoline compound |
Abstract: | Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth- oxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2.theta.(.degree.) as measured by X-ray powder diffractometry. |
Inventor(s): | Ando; Koji (Osaka, JP), Matsuda; Koji (Osaka, JP), Miyake; Shuji (Osaka, JP), Uehara; Hideto (Osaka, JP) |
Assignee: | Japan Tobacco Inc. (Tokyo, JP) |
Application Number: | 12/538,694 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,981,103 |
Patent Claim Types: see list of patent claims | Compound; Composition; Dosage form; |
Drugs Protected by US Patent 8,981,103
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Gilead Sciences Inc | STRIBILD | cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 203100-001 | Aug 27, 2012 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Gilead Sciences Inc | VITEKTA | elvitegravir | TABLET;ORAL | 203093-001 | Sep 24, 2014 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,981,103
Foriegn Application Priority Data | ||
Foreign Country | Foreign Patent Number | Foreign Patent Date |
Japan | 2004-150979 | May 20, 2004 |
International Family Members for US Patent 8,981,103
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 3281939 | ⤷ Sign Up | 122023000055 | Germany | ⤷ Sign Up |
Argentina | 049280 | ⤷ Sign Up | |||
Argentina | 096100 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |